Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Rating Upgraded by UBS Group

Arrowhead Pharmaceuticals (NASDAQ:ARWR) was upgraded by UBS Group to a “strong-buy” rating in a report issued on Wednesday, Zacks reports.

A number of other research analysts have also recently weighed in on the company. Wall Street Zen raised Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. JPMorgan Chase & Co. increased their target price on shares of Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Chardan Capital restated a “buy” rating and set a $115.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Thursday. The Goldman Sachs Group started coverage on shares of Arrowhead Pharmaceuticals in a research note on Thursday, September 24th. They set a “neutral” rating and a $74.00 target price on the stock. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $126.00 price target (up from $110.00) on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 23rd. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Arrowhead Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $99.07.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ ARWR traded down $2.60 on Wednesday, hitting $55.90. 1,772,723 shares of the company traded hands, compared to its average volume of 2,220,603. The company has a market capitalization of $7.87 billion, a price-to-earnings ratio of -24.84 and a beta of 1.29. The company has a current ratio of 5.90, a quick ratio of 5.90 and a debt-to-equity ratio of 1.77. The business’s 50 day moving average price is $75.53 and its 200-day moving average price is $75.86. Arrowhead Pharmaceuticals has a 52-week low of $36.57 and a 52-week high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The company had revenue of $75.25 million during the quarter, compared to analysts’ expectations of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%. The business’s quarterly revenue was up 171.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.26) EPS. Equities analysts expect that Arrowhead Pharmaceuticals will post -3.62 earnings per share for the current year.

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, Director Michael Perry sold 11,600 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the sale, the director directly owned 111,459 shares of the company’s stock, valued at $9,730,370.70. This trade represents a 9.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Adeoye Olukotun sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the sale, the director directly owned 31,600 shares in the company, valued at approximately $2,747,936. This represents a 5.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 3.60% of the company’s stock.

Institutional Trading of Arrowhead Pharmaceuticals

Several institutional investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter worth $1,208,838,000. Siren L.L.C. raised its position in shares of Arrowhead Pharmaceuticals by 7.7% during the 1st quarter. Siren L.L.C. now owns 1,615,476 shares of the biotechnology company’s stock valued at $101,290,000 after buying an additional 115,000 shares in the last quarter. Jupiter Topco LLC bought a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at about $99,623,000. Janus Henderson Group PLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 12.2% in the 1st quarter. Janus Henderson Group PLC now owns 1,436,990 shares of the biotechnology company’s stock valued at $90,119,000 after acquiring an additional 156,544 shares during the last quarter. Finally, Pictet Asset Management Holding SA lifted its holdings in shares of Arrowhead Pharmaceuticals by 23.8% in the 1st quarter. Pictet Asset Management Holding SA now owns 1,273,266 shares of the biotechnology company’s stock valued at $79,612,000 after acquiring an additional 244,530 shares during the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

More Arrowhead Pharmaceuticals News

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Arrowhead reported interim Phase 1/2a results for ARO-MAPT, its investigational Alzheimer’s treatment. The drug reportedly crossed the blood-brain barrier and produced up to a 73% reduction in tau, a protein associated with Alzheimer’s disease. The results support the potential of Arrowhead’s TRiM platform for delivering RNA therapies into the central nervous system. Arrowhead Reports Positive Phase 1/2a Data for Alzheimer’s Candidate ARO-MAPT
• Positive Sentiment: UBS initiated coverage of ARWR with a Buy rating and a $109 price target, while Chardan Capital and HC Wainwright reiterated Buy ratings with targets of $115 and $120, respectively. The targets reflect analysts’ confidence in Arrowhead’s pipeline and potential long-term upside. Arrowhead Pharmaceuticals Receives a New Rating from UBS
• Positive Sentiment: HC Wainwright projects Arrowhead could earn $9.61 per share in fiscal 2031, a sharp contrast with the expected loss of $3.62 per share for the current fiscal year. This highlights the firm’s view that commercialization of Arrowhead’s pipeline could significantly improve future profitability.
• Neutral Sentiment: The ARO-MAPT findings are interim, early-stage results and will require confirmation in larger, later-stage trials before they can support regulatory approval or commercial revenue.
• Negative Sentiment: After the initial data-driven surge, investors may be taking profits and reassessing valuation. Arrowhead remains unprofitable, recently missed quarterly EPS expectations, and faces substantial clinical, regulatory, and execution risks.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. Its research is based primarily on RNA interference (RNAi), a biological process that reduces the production of specific proteins by targeting messenger RNA before it can be used to make those proteins.

The company uses its proprietary Targeted RNAi Molecule (TRiM) platform to design and deliver RNAi therapeutics to selected tissues, including the liver and lungs.